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Summary The p53 tumour-suppressor gene is mutated in 60% of human tumours, and the product of the
gene acts as a suppressor ofcell division. It is thought that the growth-suppressive effects ofp53 are mediated
through the transcriptional transactivation activity of the protein. Overexpression of the p53 protein results
either in arrest in the GI phase of the cell cycle or in the induction of apoptosis. Both the level of the protein
and its transcriptional transactivation activity increase following treatment of cells with agents that damage
DNA, and it is thought that p53 acts to protect cells against the accumulation of mutations and subsequent
conversion to a cancerous state. The induction of p53 levels in cells exposed to gamma-irradiation results in
cell cycle arrest in some cells (fibroblasts) and apoptosis in others (thymocytes). Cells lacking p53 have lost this
cell cycle control and presumably accumulate damage-induced mutations that result in tumorigenesis. Thus,
the role of p53 in suppressing tumorigenesis may be to rescue the cell or organism from the mutagenic effects
of DNA damage. Loss ofp53 function accelerates the process oftumorigenesis and alters the response ofcells
to agents that damage DNA, indicating that successful strategies for radiation therapy may well need to take
into account the tissue of origin and the status of p53 in the tumour.
The cell cycle is a term used to describe the orderly sequence
of events which ensure the faithful duplication of all the
cellular components in their correct sequence and the parti-
tioning of these components into two daughter cells. Two
classes of genes and their protein products are employed to
accomplish this process: (1) genes whose products are
obligatory for progress through the cell cycle, G1 to S- to G2
to M phases, and (2) genes whose proteins act as checkpoints
which monitor the efficacy and completion of these
obligatory events and stop the progression through the cell
cycle if conditions are not satisfactory (Hartwell & Weinert,
1989; Murray, 1992). An example of an essential function is
the synthesis or activation of a set of enzymes, in late GI and
early S-phase, which are required to produce the nucleoside
triphosphate precursors for DNA replication. Without such
enzyme activities, DNA would not be duplicated and the
cycle would abort. Similarly, enzymes that duplicate the
DNA templates, the proteins that package DNA and those
involved in chromosome condensation, spindle attachment
and segregation are all essential to cell cycle progression.
Checkpoint controls monitor and regulate these events,
ensuring that initiation of each event is dependent upon
completion of the earlier event (Hartwell & Weinert, 1989).
The cell cycle will progress through each stage unless it is
stopped and restarted by a checkpoint control. Thus, most
checkpoints are not obligatory for progress through the cell
cycle, but if they should fail to function the cycle may
progress in an abnormal fashion, which could result in mis-
takes or errors in duplication or unequal segregation of
components. This may in turn lead to cell death or even the
production of abnormal cells which continue to replicate and
eventually form a tumour.
Some checkpoint controls act and stop progression of the
cell cycle, by modifying a group of essential proteins called
the cyclins. Cyclins bind to and activate the catalytic subunits
of protein kinases, termed cyclin-dependent kinases (cdk),
which in turn phosphorylate a set of targets that drive the
cycle through GI to S- to G2 and M phases (Hartwell &
Weinert, 1989; Herskowitz et al., 1991). Other checkpoint
functions modify phosphorylation of the cyclin-dependent
kinase itself, which contributes to the regulation of the
activity of the kinase complex (Murray, 1993; Walworth et
al., 1993). Events external to the cell, such as the availability
of nutrients or growth factors, influence checkpoint pathways
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which regulate the level or ability of cyclins to activate these
cyclin-dependent kinase activities in a cell. In some cases, the
checkpoint control circuit is stimulated by a signal transduc-
tion pathway, which in itself may be composed of a cell-
surface receptor, a GTP-binding protein-GTPase, protein
kinase activities and transcription factors (Herskowitz et al.,
1991). This signal transduction pathway is sensitive to factors
such as external nutrient levels, and communicates to a
checkpoint control that alters the level or activity of the
cyclins and their kinases (Figure 1).
While a large number of experiments with yeast, Xenopus
and mammalian cells have led to this outline of events in the
cell cycle, other approaches have identified the same sets of
genes and gene functions as playing a critical role in the
origins of cancer in human beings. It is becoming clear that
cancer arises in humans because of the accumulation of
mutations in two major classes of genes: the proto-oncogenes
and the tumour-suppressor genes (Brugge et al., 1991;
Levine, 1992a). While a wide variety of diverse mechanisms
may lead to mutations which contribute to cancer, there are
three general results of these mutations: the overexpression of
a gene and its product, the alteration of a gene product and
the inactivation of the encoded protein. Oncogenes result
from activating mutations which either raise the level of a
protein in a cell or alter its function by mutation in the
structural gene. Tumour-suppressor genes are commonly
inactivated, resulting in a loss of function mutation. For
these reasons, oncogene mutations are usually dominant to
the wild-type allele, while tumour-suppressor genes are most
commonly recessive to the normal allele. Increased levels of
oncogene products are achieved by gene amplifications or
chromosomal translocations, which bring together an
oncogene and a region of DNA encoding signals for high
rates of transcription. For example, the N-myc gene is found
in high copy numbers (amplification) in some neuroblas-
tomas while the c-myc oncogene is found in a translocated
chromosome fragment adjacent to the immunoglobulin locus
in some B-cell tumours (Brugge et al., 1991). Other
oncogenes, such as ras, are found to have a mutation in the
structural gene which alters as specific amino acid and
changes the regulation of this protein. The result of such a
mutation is the continuous signalling for cell growth via an
activated signal transduction pathway.
Conversely, the loss of function observed with tumour-
suppressor genes corresponds to an increased risk for cancer.
Tumour-suppressor genes are responsible for the inherited
predispositions to cancer in human populations (see Table I)
as seen with the p53 gene, the retinoblastoma susceptibility
'." Macmillan Press Ltd., 1994 Br. J. Cancer (1994), 69, 409-416410 A.J. LEVINE et al.
Table I Tumour suppressor genes
Chromosome,
Tumour name Syndrome
1. Retinoblastoma 13ql4, Rb Familial
retinoblastoma
2. Wilms' tumour llpl3, WT-1 Wilms' tumour,
Beckwith-Wiedemann
3. Colorectal cancer 5q21, APC Familial polyposis
4. Osteogenic 17pI3, p53 Li-Fraumeni
sarcoma, several
carcinomas
gene (Rb), the adenomatous polyposis coli gene (APC), or
Wilms' tumour gene (WT-1) (Levine, 1992a). These muta-
tions carried in a heterozygous state in the germ line predis-
pose individuals to high risk for specific cancers. Mutations
in the Rb and APC gene tend to be classical loss of function
mutations, such as chain termination mutations, deletions,
exon-skipping mutations or frameshift mutations. The gene
product is inactivated. Insertional mutations in mice,
eliminating both normal alleles of the Rb gene (Clarke et al.,
1992; Jacks et al., 1992; Lee et al., 1992) or the p53 gene
(Donehower et al., 1992), permit cell division to occur in the
developing embryo (these are therefore non-essential func-
tions of the cell cycle), but these mutations predispose the
mice to a higher incidence of cancer [in the heterozygous
state for Rb (Jacks et al., 1992) and the homozygous or
heterozygous state for p53 (Lavigueur et al., 1989;
Donehower et al., 1992)]. Somatic mutations in tumour-
suppressor genes also contribute to the origins of cancer in
humans (Levine, 1992b). Commonly, one allele of a tumour-
suppressor gene sustains a mutation which inactivates the
function of its protein and then the second allele is lost via
deletion or gene conversion, resulting in a loss of
heterozygosity (LOH) or a reduction to homozygosity at that
locus in the cells of the tumour (Levine et al., 1991). Return-
ing the wild-type allele to the cancer cell will result in a loss
of tumorigenic potential of that cell (Huang et al., 1988).
Elucidation of the functions of oncogene products have
shown them to be components of the very signal transduc-
tion pathways that connect some checkpoint controls to the
essential functions of the cell cycle: (a) growth factors, (b)
receptors, (c) GTP-binding proteins, (d) protein kinases and
(e) transcription factors (Figure 1). Some of the tumour-
suppressor genes, such as p53 and Rb, have many of the
properties of checkpoint controls: they are non-essential for
cell division; they can negatively regulate or stop cell
division, often in response to outside signals; and they may
monitor the efficiency or completion of a process in the cell
cycle. Thus, the tumour-suppressor genes and oncogenes are
External signals (nutrient level, growth factor level)
Receptor, GTP-binding protein-GTPase
Kinase cascade
Cyclin degradation
I Inactive cyclin-dependent kinase 1cin ctive cyclin-dependent kinase
l -l
Stop cell cycle START-_ DNA replication
Figure 1 Cell cycle progression is regulated by the activity of the
cyclin-dependent kinases, which can be stimulated by a signal
transduction pathway sensitive to external factors. These signal
transduction pathways are composed of proteins which, in mam-
malian cells, are encoded by the proto-oncogenes and tumour-
suppressor genes.
starting to take their place in the events of the cell cycle
(Figure 1).
This article will focus upon one of the tumour-suppressor
genes, p53. The protein encoded by this gene appears to play
a role as a checkpoint control for recognising DNA damage
(Kuerbitz et al., 1992), resulting in either a delay in progress
through the cell cycle to permit repair processes (Kastan et
al., 1991) or the initiation of programmed cell death or
apoptosis (Lowe et al., 1993), eliminating the abnormal
clones of cells that could lead to cancer. There is a growing
body of evidence that p53 monitors genomic stability. Cells
that have no p53 protein are at least one million times more
likely to permit DNA amplifications than cells with normal
levels of p53 protein (Livingstone et al., 1992; Yin et al.,
1992). Such amplifications are common events in some
cancers.
The nature of mutations at the p53 locus
Two lines of evidence clearly demonstrate that p53 is a
tumour-suppressor gene. First, about 60% of cancers in
humans have mutations in the p53 gene (Levine et al., 1991).
Commonly, this takes the form of a missense mutation plus a
selection for a reduction to homozygosity and thus a com-
plete loss of the wild-type alleles (Levine et al., 1991). This is
the hallmark of a tumour-suppressor gene. Second, mice that
contain mutations in both p53 alleles that eliminate p53
functional proteins are normal at birth, but 100% of these
mice develop cancers in a 6-9 month period (Donehower et
al., 1992). These null mutations prove that the loss of p53
function results in a predisposition to cancer.
There are, however, several observations which suggest
that the nature of p53 mutations in cancers is more complex
than a simple loss of function. First, 85.6% of the mutations
at the p53 locus in human cancers are missense mutations,
resulting in a faulty or altered protein in the cell (Levine et
al., 1993). This contrasts with other tumour-suppressor genes
(Rb, APC) which have much higher frequencies of chain
termination codons, deletions, exon-skipping mutations or
frameshift mutations. Only 8.1% of the p53 mutations are
deletions or insertions (and one-fifth of these still produce
proteins in reading frame), 5.5% are nonsense mutations or
frameshift mutations and 0.8% of these mutations are neut-
ral and produce no amino acid changes (these data are
summarised from 1,447 mutations from cancers of 51
different cell and tissue types; Levine et al., 1993). Further-
more, when this spectrum of mutations is analysed for the
position of missense mutations in the p53 gene (with 393
codons), the great majority of mutations (92.1%) are
localised between codons 120 and 290 (see Figure 2). The
nature of the few mutations found outside of this region of
the gene is instructive. For example, six independent muta-
tions each have occurred at codon 298 and codon 342, and
all 12 of these mutations are chain termination mutations.
Codon 53 contains four independent mutations, and three of
these are also chain termination mutations (Levine et al.,
1993). Clearly, missense mutations are selected for between
codons 120 and 290, while nonsense mutations are much
more common outside of this region. The chain termination
codons more likely result in a loss of function mutation.
While it is clearly true that most of the experiments that
provide nucleotide sequences of mutant p53 cDNAs have
focused only on the region between codons 120 and 290 (and
so there may well be a bias to find mutations in this region),
the qualitative differences between the nature of the muta-
tions occurring inside or outside of the central portion of the
gene suggests that there is a selection for missense mutations
in one of the protein domains of the p53 gene. It is this
conclusion which is at odds with an expected simple 'loss of
function' mutation or a simple classification as a tumour-
suppressor gene.
Indeed, missense mutant p53 proteins do exhibit several
phenotypes or activities that suggest they actively contribute
in some fashion to abnormal cell growth. Missense mutantTHE p53 TUMOUR-SUPPRESSOR GENE 411
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Figure 2 The spectrum of 1447 mutations in the p53 protein
from all types of human tumours.
p53 genes can cooperate with an activated ras oncogene and
transform primary rat embryo fibroblasts in cell culture
(Eliyahu et al., 1984; Parada et al., 1984). Similarly, missense
p53 mutant alleles enhance the colony-forming ability or
plating efficiency of primary rat cells in culture (Finlay et al.,
1989). In these cases, it is thought that the faulty p53 protein
forms a tetrameric protein complex with the endogenous
wild-type p53 protein in the cell, and such mutant-wild type
complexes, which have been demonstrated to exist (Finlay et
al., 1988; Martinez et al., 1991), inactivate the functions of
the wild-type p53 protein. This is a dominant loss of function
phenotype which can explain how mutant p53 proteins
actively contribute to cell transformation and, in this way,
act like oncogenes (Finlay et al., 1989). The mutant missense
p53 proteins also possess a gain of a new function
phenotype. If one introduces a mutant p53 missense allele
into a cell that has no p53 gene or protein (is null for p53
function), then these cells show an enhanced ability to induce
tumours in nude mice (Dittmer et al., 1993). Since these cells
contain no endogenous wild-type p53 proteins to be inac-
tivated by the p53 mutant protein, these data indicate that
the altered p53 protein itself can contribute a new function to
these cells (Dittmer et al., 1993).
These observations indicate that the p53 missense mutants
have lost some functions, as expected for a tumour-
suppressor gene, but have also gained new activities and
therefore this gene is more like an hermaphrodite in the
scheme of oncogenes and tumour-suppressor genes. This may
account for the fact that mutations at the p53 locus are the
single most common genetic alteration now observed in
human cancers. The p53 gene is found in a mutant form in
about 70% of colorectal cancers, 50% of lung cancers and
30-40% of breast cancers (Levine et al., 1991).
A role for tissue-specific mutagens in the environment
While these observations and arguments strongly implicate
the role of selection for specific mutations in shaping the
spectrum or distribution of mutations observed in the p53
gene, other forces appear to play an important part in this
process. Figure 3 shows the distribution of p53 mutations in
specific cancers of the colon, lung, breast and liver. These
distributions of p53 mutations share some similarities, but
some mutant alleles are preferred or are unique to the cell or
tissue type of the cancer. Such differences might arise from
either tissue-specific selection of a particular mutant allele or
from the exposure of different tissues to different environ-
mental mutagens, which could act to produce a distinct type
of mutation in these tissues. If this latter hypothesis were
correct, the different mutations specific to a tissue type would
result from the nature of the mutagen exposure and its
specific mode of action. The mutational profiles in Figure 3
would be a kind of 'Ames test' carried out in the human
population at the p53 locus. There is some evidence in favour
of this idea. Figure 4 contrasts the frequency of transition
mutations and transversion mutations observed in the p53
gene from cancers of different tissues. Since distinct mutagens
initiate these different types of mutations, the significant
differences in the ratio of transition to transversion mutations
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Figure 3 The distribution of p53 mutations in human tumours
from colon, lung, breast and liver.
in each tissue is most consistent with the idea that different
mutagens act upon different tissues of the body. For exam-
ple, lung cancers show more transversion mutations than
colon or stomach cancers. This may be expected from the
mutagens in cigarette smoke, such as benzpyrene, which
preferentially produce transversion mutations. Codon 157
mutations are found almost exclusively in lung tumours
(Figure 3) and are always transversion mutations. In a
similar fashion, all of the basal cell carcinomas and most of
the squamous cell carcinomas of the skin result from the
mutations caused by ultraviolet light (pyrimidine photo-
products) and are solely transition mutations. Finally, the
common mutation at codon 249 of hepatocellular carcinomas
derived from specific geographic locations, such as southern
China and the southern parts of Africa (Bressac et al., 1991;
Hsu et al., 1991), most probably arise from the presence of
the fungus that produces aflatoxin B1 in peanut crops of
those areas. In regions where peanut crops are inspected and
aflatoxin Bl eliminated, the mutation at this codon occurs at
a much lower frequency.
Thus, it appears likely that the unusual distribution of p53
mutations seen in Figures 2 and 3 derives from a combina-
tion of the diverse mutagens inducing these events, which
appear to differ for different tissues, and by selection for a
mutant missense allele with a particular altered phenotype
that may contribute to abnormal cell cycle events.
The p53 tumour-suppressor gene and its protein
The p53 gene is located in 16-20 kb of DNA on the short
arm of human chromosome 17, at position l7pl3.1 (Ben-
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gene (Seto et al., 1992). p53 mutant proteins also fail to bind
to TBP and inhibit transcription of a gene of this type. This
is a second loss of function phenotype for p53 missense
mutations.
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chimol et al., 1985). The gene is composed of 11 exons, and
the first exon, which is 213 base pairs, does not encode
information for the protein. This exon is located 8-10kb
away from the second exon which contains the translational
start codon. The p53 transcript is spliced to produce a
2.2-2.5 kb mRNA species that is synthesised in all cells of
the body. The thymus, spleen, testes and ovary have the
highest concentration of p53 mRNA (Rogel et al., 1985).
The p53 gene has been conserved over evolutionary time
scales. The murine and human p53 proteins are about 80%
homologous and the human and Xenopus p53 proteins are
about 56% homologous (Soussi et al., 1987). There are five
regions of the p53 protein where amino acid sequence iden-
tities approach 100% over stretches of up to 20 amino acids.
These are termed conserved regions I, II, III, IV and V and
correspond to codons 13-19, 120-143, 172-182, 238-259
and 271-290 respectively (out of a total of 393 amino acids).
Sixty-eight per cent of the p53 missense mutations reside in
conserved regions II, III, IV and V, while 86% of p53
mutations are located between codons 120 and 290. Both this
distribution of mutations and the conservation of amino acid
sequences in this region of the protein suggest that an impor-
tant functional domain resides in this region of the protein.
Indeed, the amino acid residues of the p53 protein have now
been divided into three distinct functional domains; The
amino-terminal 75 amino acids are quite acidic, and when
this portion of the gene is fused with a known DNA-binding
protein, the Gal4 protein from yeast, then this Gal4-p53
fusion protein can enhance the transcription of a gene with a
Gal4 DNA-binding element (Fields & Jang 1990; Raycroft et
al., 1990). Thus, the amino-terminal 75 amino acid residues
can act to promote transcription if brought to the DNA by a
DNA-binding domain. The region of the p53 protein
between residues 120 and 290 can act as a specific DNA-
binding domain, interacting with a p53 recognition element.
The consensus nucleotide sequence for p53 binding to DNA
is 5'-Pu-Pu-Pu-C-A/T-A/T-G-Py-Py-Py-3' (El-Diery et al.,
1992; Funk et al., 1992). The carboxy-terminal domain com-
posed of amino acid sequences 290-393 contains a set of
nuclear localisation signals (Shaulsky et al., 1991), a site for
phosphorylation by a cyclin-dependent kinase (Stuzbecher et
al., 1990) and a region that promotes the protein to form
tetramers or other oligomeric forms in solution (Stenger et
al., 1992). Thus, the p53 protein is a transcription factor that
enhances the rate of transcription of a gene that has a p53
responsive element, and this has been shown both in vivo
(Zambetti et al., 1992) and in vitro (Farmer et al., 1992). The
missense mutations found in the p53 gene from cancerous
cells produce a faulty protein that no longer binds as
efficiently to this specific DNA sequence (mutations are
clustered in the DNA-binding domain) (Bargonetti et al.,
1991) and no longer promotes the transcription of a gene
with the p53 responsive element (Kern et al., 1991). This is
the phenotype of one of the loss of function mutations at the
p53 locus.
For many genes that do not contain a p53 responsive
element in their regulatory regions, the p53 protein inhibits
or negatively regulates transcription (Zambetti & Levine,
1993). The p53 protein has been shown to bind to one of the
basal transcription factors, the TATA-binding protein (TBP),
and this interaction is thought to block transcription of a
The consequences of mutation at the p53 gene
InheritedpS3 mutant alleles
The Li-Fraumeni syndrome (Li et al., 1988) was originally
described in families in which a proband was diagnosed with
a sarcoma early in life and then two first-degree relatives
were detected under the age of 45 with cancer of any type.
Many of the Li-Fraumeni families were then shown to have
p53 mutations in the germ line and, when carried in the
heterozygous state, the individual was at very high risk for
cancer (Malkin et al., 1990; Srivastava et al., 1990). This
definition has been recently extended to include larger family
groupings with multiple neoplasms in whom sarcomas
(especially osteogenic sarcoma) are detected early in life
(Levine, 1992b; Toguchida et al., 1992). The cancers that
arise in these families contain the mutant allele and com-
monly a reduction to homozygosity at this locus so that no
wild-type alleles are present in the cancer. Transgenic mice
that inherit one mutant p53 allele also have a higher than
normal frequency of cancer in their offspring (Lavigueur et
al., 1989). Mice with no p53 wild-type alleles all develop
cancer in 6-9 months (Donehower et al., 1992).
Somatic mutations at the p53 locus
Somatic p53 mutations occur in a wide variety of cancers (at
least 50 different cell or tissue types). Some cancers have a
high percentage of p53 mutations (colorectal, 70%; small-cell
lung cancer, 100%) (Hollstein et al., 1991; Levine et al.,
1991), while other cancers never seem to accumulate p53
mutations (neuroblastoma, testicular teratocarcinoma, acute
lymphatic leukaemia) (Jonveaux & Berger, 1991; Heimdel et
al., 1993). A number of recent studies have indicated that the
presence of a p53 mutation in a particular cancer indicates a
poor prognosis for response to chemotherapeutic treatment
and survival (Callahan, 1992). The rationale for this correla-
tion is becoming clear as the functions of the p53 protein are
explored, and these concepts will be detailed in the next
section.
Returning the wild-type p53 gene into cancer cells (Mercer
et al., 1990) or cells being transformed by oncogenes (Finlay
et al., 1989) blocks transformation and reduces the
tumorigenic potential of these cells. Cells transformed by a
temperature-sensitive mutant of the p53 gene replicate
rapidly at 39°C, but fail to duplicate at 32°C (Martinez et al.,
1991; Michalowitz et al., 1991). In these cells, the p53 protein
is preferentially in the mutant form at 39°C and the wild-type
form at 32°C (Martinez et al., 1991; Michalowitz et al.,
1991). The wild-type protein blocks these cells from progress-
ing past GI (Martinez et al., 1991) and therefore acts as a
checkpoint in late GI of the cell cycle. Mutant p53 proteins
fail to act as transcription factors and fail to regulate this GI
arrest so it is tempting to speculate that p53-mediated trans-
cription of several critical genes is required to block progres-
sion of GI to S-phase and that this control is lost in
cancerous cells.
The regulation of the p53 protein by oncogenes
The DNA tumour viruses, simian virus 40, the human
adenoviruses and the human papillomaviruses, encode
oncogene products that can transform cells in culture and
initiate tumours in animals or, in the case of some papil-
lomaviruses, in humans (zur Hausen & Schneider, 1987). The
oncogene products of these three diverse groups of viruses
target two of the cellular tumour-suppressor gene products:
Rb and p53. The SV40 large T antigen binds to Rb (DeCap-
rio et al., 1988) and p53 (Lane & Crawford, 1979; Linzer &
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Levine, 1979) in transformed cells and inactivates the func-
tions of these putative checkpoint controls. p53 in a T
antigen-p53 complex can no longer bind to a p53 responsive
DNA element and fails to act as a transcription factor
(Mietz, et al., 1992). Similarly, the adenovirus E1B 55 kDa
protein (an oncogene product) binds to p53 protein (Sarnow
et al., 1982) and blocks its ability to act as a transcription
factor (Yew & Berk, 1992). In this case the EIA oncogene
product of adenovirus binds to Rb (Whyte et al., 1988). The
human papillomaviruses encode two oncogenes, termed E6
and E7 (Munger et al., 1992). The E6 protein binds to p53
(Werness et al., 1990) and the E7 protein to Rb (Dyson et
al., 1989) (see Table II). The E6-p53 complex is targeted for
proteolytic degradation, utilising the ubiquitin system, result-
ing in a loss of p53 protein and therefore a loss of p53
function in these cells (Scheffner et al., 1990). Thus, three
quite diverse virus groups, each capable of initiating tumours
in humans (papillomaviruses) or animals, have targeted the
major tumour-suppressor gene products of the cell, Rb and
p53. Importantly, these virus-encoded oncogene products
inactivate p53-mediated transcription much like the muta-
tions observed in the p53 gene from human cancers.
Recently, a cellular protein encoded by an oncogene,
termed mdm-2 (Fakharzadeh et al., 1991), has also been
shown to bind to the p53 protein and inactivate its ability to
function as a transcription factor (Momand et al., 1992).
When the mdn-2 gene is amplified in mouse cells (Fakhar-
zadeh et al., 1991), the elevated levels of mdm-2 proteins
enhance the tumorigenic potential of these cells. Whether
mdm-2 proteins act by inactivating the wild-type p53 protein
or have an intrinsic activity of their own remains to be
determined. In either case, a number of human sarcomas -
liposarcoma, osteogenic sarcoma or fibrous histiocytic sar-
comas - contain amplified copies of the mdn-2 gene (Oliner
et al., 1992). Some of these tumours have both mdn-2
amplifications and p53 mutations (about 10%), and this
group has a poorer prognosis for long-term survival than
sarcoma patients with no p53 or mdn-2 mutations or
patients with p53 or mdn-2 mutations alone (Cordon-Cardo
et al., 1993). Clearly, gene functions that regulate the p53
gene or gene product will act as either oncogenes (negative
regulation) or tumour-suppressor genes (positive regulation)
and these regulatory proteins will be central to our under-
standing of cancer in humans.
The functions of the p53 gene product
The levels of p53 protein in a cell are dramatically increased
(5 to 60-fold) in response to exposure to DNA-damaging
agents such as UV or gamma-irradiation or chemicals that
react with DNA (Maltzman & Czyzyk, 1984; Kastan et al.,
1991). After gamma-irradiation, double-stranded breaks in
the DNA must be repaired prior to DNA replication,
chromosome packaging and segregation. If the damaged
DNA participates in replication or chromosome segregation,
then mutations occur at a high frequency and chromosome
segregation may be faulty. This results in a high rate of cell
death and rare mutant clones of cells that grow in an uncon-
trolled fashion. After gamma-irradiation, the high p53 levels
block progression of the cell cycle in the GI phase, so as to
permit DNA repair prior to proceeding with DNA replica-
tion (Kuerbitz et al., 1992). The increased levels ofp53 result
from an enhanced stability of the p53 protein. In response to
DNA damage, the half-life of the p53 protein increases from
20-30 min in normal cells to hours in cells that were recently
irradiated (Maltzman & Czyzyk, 1984; Kastan et al., 1991).
Thus, the p53 protein acts as a checkpoint control in the cell
cycle, blocking progression of cells in GI and preventing
entry into S-phase, in response to an environmental insult.
This does not permit the duplication of damaged DNA and
minimises errors in the cell cycle. p53 enhances the fidelity of
the cell cycle by monitoring cells for damaged DNA.
One of the mutations that results from DNA exposed to
gamma-irradiation is gene amplification. The single- and
double-strand ends of broken DNA are aggressive recom-
bination intermediates, and unequal crossing over or gene
conversion duplicates genetic loci, which are subsequently
amplified into many copies of DNA. Such mutations are of
course the hallmark of several oncogene mutations (Brugge
et al., 1991). Cells with no p53 proteins (null mutations) will
amplify their DNA at least one million times more readily
than observed in cells containing wild-type p53 protein (Liv-
ingstone et al., 1992; Yin et al., 1992). Thus, a growing body
of evidence indicates that the p53 protein monitors the inte-
grity of the genome and minimises the mutations which arise
from exposure to DNA-damaging agents.
The p53 protein might accomplish this in one of several
ways. The enhanced levels ofp53 protein should regulate the
transcription of a set of genes with p53 responsive elements.
To date, two such genes have been identified.
(1) GADD-45 is a gene whose level of transcription is
increased in response to DNA damage and whose levels are
highest in resting or non-cycling cells (Fornace et al., 1989).
The gene for GADD-45 contains a p53 responsive element in
the third intron, and p53 protein isolated from irradiated
cells binds to this DNA element (Kastan et al., 1992).
(2) The mdn-2 gene, contains a p53 responsive element in
the first intron of this gene, and p53 protein has been shown
to bind specifically to this DNA sequence (Wu et al., 1993).
mdm-2 is an oncogene whose product might be expected to
promote entry of cells into cycle or S-phase. Thus, p53 may
utilise the regulation of GADD-45 to block progression
through the cell cycle in GI and mdm-2 to reverse this process
and commit cells to S-phase after the DNA repair process.
At high doses of ultraviolet light, cells induce p53 to high
levels and the induction of mdm-2 mRNA and protein is
delayed, occurring about the same time cells enter S-phase
(Perry et al., 1993). Thus, p53 could control the transcription
of a set of genes to block cells in GI and then overcome this
block to permit re-entry into the cycle. In this case, addi-
tional factors would control when p53 stimulates transcrip-
tion of GADD-45 and mdm-2 genes (Perry et al., 1993) (see
Figure 5).
Table II Viral oncogene-tumour-suppressor gene interactions
Viral oncogene Cellular protein Reference
1. SV40 large T antigen
a. amino acid residues 105-114 Rb DeCaprio et al. (1988)
b. amino acid residues 400-650 p53 Linzer & Levine (1979)
Lane & Crawford (1979)
2. Adenoviruses, type 5
a. the E1A proteins Rb Whyte et al., 1988)
amino acid residues 40-80
and 121-139
b. the E1B 55 kDa p53 Sarnow et al. (1982)
3. Human papillomaviruses
types 16, 18
a. E6 p53 Werness et al. (1990)
b. E7 Rb Dyson et al. (1989)414 A.J. LEVINE et al.
p53
IGamma-irradiation
p53
Apoptosis G1 arrest
(thymocytes) (fibroblasts)
Figure 5 The level and specificity of p53 transcriptional transac-
tivation activity in response to DNA damage may be regulated
by other transcription factors.
In some cell types, enhanced levels of p53 protein appear
to direct the cells into a pathway for programmed cell death
or apoptosis (Yonish-Rouach et al., 1991; Shaw et al., 1992).
In thymic T cells derived from mice with wild-type p53
protein, exposure to ionising radiation induces apoptosis. In
thymic T cells derived from mice with no p53 protein (null
mutations), exposure to irradiation fails to lead to program-
med cell death (Clarke et al., 1993; Lowe et al., 1993). Thus,
the DNA damage utilises the p53 protein pathway to commit
to apoptosis. For cells damaged so badly that efficient repair
is not feasible, a pathway to cell death is preferable to sustain
the life of the organism. Mutations in the p53 gene would
then permit abnormal cell clones to arise after DNA damage.
It is relevant that the most common tumour type observed in
mice homozygous for the p53 null alleles is a T-cell lym-
phoma (Donehower et al., 1992).
Cancers containing a wild-type p53 allele have a better
prognosis for responses to chemotherapy and survival than
cancers with p53 mutations (Callahan, 1992). It is of con-
siderable interest then that these interpretations of the func-
tions of the p53 protein predict how radiation or cancer
chemotherapy acts to preferentially kill cancerous cells and
not normal cells. Most chemotherapeutic agents and radia-
tion treatments damage DNA. In normal cells or cancer cells
with wild-type p53 proteins, this induces high p53 levels,
which then may block cells in GI to permit DNA repair or, if
the damage is very extensive, kill the cells via apoptosis.
Cancer cells with p53 mutations enter S-phase and duplicate
damaged DNA. They segregate their chromosomes abnor-
mally, and these processes result in a good deal of cell death.
These cells also fail to enter into the pathway for apoptosis
even with extensively altered DNA. The result is the progres-
sive appearance of more abnormal cells and clones of cells
that evolve into more aggressive cancers.
If these ideas are correct, it will become important to
determine the status of the p53 gene and the mdn-2 gene in
cancer cells so as to determine the best treatment protocols
(Lowe et al., 1993). Similarly, individuals with germline p53
mutations (Levine, 1992b) who develop cancers may well
need to be treated differently from those whose normal cells
are homozygous for both p53 wild-type alleles.
The available evidence favours a role for the p53 protein
as a checkpoint in cell cycle progression, permitting repair of
DNA damage and prevention ofgene amplifications. In some
cell types, high levels of p53 protein act as a switch to turn
on a pathway to apoptosis in a cell responding to DNA
p53
j UV light
p53
Intron 1 mdm-2 gene
mdm-2 mRNA
Intron 3 GADD45 gene
GADD45 mRNA
Figure 6 DNA-damaging agents induce different p53-dependent
responses in different cell types.
alterations (see Figure 6). It appears likely that p53 can
mediate these activities, probably by its functioning as a
transcription factor. To date we know of only two clear
examples of genes regulated by p53 transcriptional transac-
tivation activity (Kastan et al., 1992; Wu et al., 1993),
GADD45 and mdn-2. There are probably other genes
regulated by high p53 protein levels, and the search for them
will be an important avenue for future efforts. In addition,
the modulation of p53 transcriptional activation by other
gene products will need to be understood (see Figure 5) and
explored in future experimentation. For example, the expres-
sion of the mdm-2 gene is autoregulated because it has a p53
responsive element and, when more mdm-2 protein is syn-
thesised, it binds to p53 protein and reduces p53-mediated
transcriptional activation (Momand et al., 1992; Wu et al.,
1993). There are probably additional positive and negative
regulators of p53 synthesis and/or activity. It remains pos-
sible that the p53 protein plays a direct role (not only via
transcription of other genes) in the process of monitoring
DNA damage or recombination intermediates in a cell. The
p53 protein itself binds with high affinity to single-strand
DNA and RNA and catalyses the annealing of these nucleic
acids into double-stranded DNA or RNA (Oberosler et al.,
1993). It would be expected that the p53 protein should
antagonise critical helicase activities utilised in DNA replica-
tion and recombination. This could block aggressive single-
strand recombination intermediates that lead to gene duplica-
tions, amplifications and oncogene activations. Thus, it re-
mains possible that the p53 protein monitors the integrity of
the host genome by acting directly upon DNA as well as via
the regulation of other gene products. Elucidating the func-
tions of the p53 protein will go a long way to understanding
the origins of human cancers.
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